Purpose This study assessed the association between the severity of diabetes complications using diabetes complications severity index (DCSI) and stage of breast cancer (BC) at diagnosis among elderly women with pre-existing diabetes and incident BC. Methods Using Surveillance, Epidemiology and End Results-Medicare data, we identified women with incident BC during 2004-2011 and pre-existing diabetes (N = 7729). Chi-square tests were used to test for group differences in stage of BC at diagnosis. Multinomial logistic regression was used to examine the associations between the severity of diabetes complications and stage of BC at diagnosis. Results Overall, women with a DCSI = 2 and a DCSI C 3 were more likely to be diagnosed at advanced stages as compared to those with no diabetes complications. In full adjusted association (after adding BC screening to the analysis model), the severity of diabetes complications was no longer an independent predictor of advanced stages at diagnosis. However, women with a DCSI = 2 were 26% more likely to be diagnosed at stage I (versus stage 0) of BC at diagnosis as compared to those without diabetes complications (OR 1.26, 95% CI 1.03-1.53). Conclusion The increased likelihood of having advancedstage BC at diagnosis associated with severity of diabetesrelated complications appears to be mediated by lower rates of breast cancer screening among elderly women with pre-existing diabetes complications. Therefore, reducing disparity in receiving breast cancer screening among elderly women with diabetes may reduce the risk of advanced-stage breast cancer diagnosis.
Introduction
Several previous studies have found that women with diabetes were more likely to be diagnosed in advanced stages of breast cancer (BC) as compared to those without diabetes mellitus (DM), and this may contribute to their higher mortality after cancer diagnosis [1] [2] [3] [4] . Many reasons have been put forward to possibly account for later stage diagnosis of BC among women with diabetes. Studies have showed that women with diabetes are more likely to be diagnosed with metastatic and larger tumors as compared to those without diabetes [5] . Lower rates of screening mammography among women with diabetes could also account for later stage diagnosis of BC, although women with diabetes have more frequent primary health care visits than women without diabetes [6] . This lower rates of BC screening could play a role in the association between diabetes and risk of advanced stages of BC at diagnosis.
Age and age-related changes also play a crucial role in the association between diabetes and advanced-stage diagnosis of BC. Elderly women with diabetes are more likely to be diagnosed at advanced stages of breast cancer [7] [8] [9] , with more frequent pre-existing diabetes-related complications as compared to younger population [9] .
Since elderly women with DM have a higher likelihood of complications and advanced stage BC, it is important to determine how the severity of these complications contributes to advanced-stage BC at diagnosis. Thus, the aim of this study is to determine the association between the severity of diabetes complications and stage of BC at diagnosis in women with incident BC and pre-existing diabetes. We hypothesized that stage of BC at diagnosis is associated with severity of diabetes complications in elderly women with incident BC and pre-existing diabetes.
Methods Study design and data source
This was a retrospective observational study in a cohort of elderly women with incident BC diagnosis and pre-existing diabetes. The cohort was followed retrospectively for 24 months prior to the BC diagnosis to assess the association between the severity of diabetes complications and stage of BC at diagnosis.
We used the US Surveillance Epidemiology and End Results (SEER)-Medicare data. Information of individuals in the SEER database who have been matched with Medicare enrollment records is in a customized file known as the Patient Entitlement and Diagnosis Summary File (PEDSF) [10] . The linked claims database consists of Medicare Provider Analysis and Review (MEDPAR), the Carrier Claims (old name Physician/Supplier (NCH)), Outpatient (OUTPT), Home Health Agencies (HHA), Hospice, Durable Medical Equipment (DME) and Part D Event (PDE) files [10] . These files in Medicare data have been linked with PEDSF file of cancer cases from SEER using an algorithm, and based on the linkage, a common identification number is given to each enrollee in PEDSF and claims files [11, 12] .
We also linked the Area Resource File (ARF) [13] to the SEER-Medicare dataset using the state and county Federal Information Processing Standards code for each beneficiary to extract the county level information on the availability of mammography facilities.
Study cohort
Our cohort consisted of elderly women aged 67 years or older with the first primary diagnosis of incident BC between January 1, 2004 and December 31, 2011 who had pre-existing diabetes. Women must have at least 24 months of continuous enrollment in Medicare part A and B prior to the BC diagnosis and must have no enrollment in a health maintenance organization (HMO) at any time during the study period. Diabetes was determined on the basis of either a single inpatient claim or at least two outpatient claim diagnoses with International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis code of 250.xx during the 12 months that preceded BC diagnosis [14] . Women who were diagnosed with BC via death certificate or autopsy, or were with any previous cancer diagnosis, unknown, or missing BC stage information were excluded from the study cohort (Fig. 1) .
Measures
The dependent variable was cancer staging based on the American Joint Committee on Cancer's staging system. Stage at diagnosis (0-IV) of the cancer/tumor was taken from PEDSF file. For the study purpose, we grouped our cohort into four categories: elderly women with stage 0, stage I, stage II, and advanced stage (III & IV) at BC diagnosis.
The key independent variable was the severity of diabetes-related complications which was identified during the 12 months that preceded the BC diagnosis. The severity of diabetes-related complications was measured using the diabetes comorbidity severity index (DCSI) [15] [16] [17] . The DCSI was first developed by Young and colleagues to include seven categories of diabetes complications: cardiovascular disease, nephropathy, retinopathy, peripheral vascular disease, cerebrovascular, neuropathy, and metabolic complications. Theses complications were identified using ICD-9-CM diagnosis code [15] . The index for each complication was categorized into 2 or 3 levels (no abnormality = 0, some abnormality = 1, and severe abnormality = 2), based on the presence and severity of the complication, and the indices of all complications were added together to get the DCSI which is a 13-point scale with a range of 0-13 [15, 16] . The study cohort was divided into 4 subgroups consisting of DCSI = 0, DCSI = 1, DCSI = 2, and DCSI C 3.
Other independent variables included biological factors, non-biological factors, and mammography screening use. The biological factors were age at diagnosis, race, hormone receptor status (HR), and other comorbid conditions. Age at BC diagnosis and race were decided using the SEER PEDSF file. Age at diagnosis was categorized as follows (in years): 67-70, 71-74, 75-79, and 80 or older. Race was categorized based into ''White,'' ''African-American,'' or ''Other''. The HR was categorized into positive, negative, and borderline/unknown. The pre-existing comorbid conditions were measured as the presence or absence of the following chronic conditions: thyroid syndrome, arthritis, asthma, Chronic Obstructive Pulmonary Disorder (COPD), dementia, hyperlipidemia, hypertension, osteoporosis, anxiety, and depression. These comorbid conditions were identified using ICD-9 diagnosis codes in the Medicare inpatient and outpatient claims.
The non-biological factors included access to health care (primary care providers (PCP) visits, endocrinologist visits, and availability of BC screening facilities in county of women's residence) and community-related factors (census tract median annual household income, census tract-level education, geographic region of residence, and metropolitan status). We defined PCP as providers who had the following specialties: general practice, family medicine, , and ICD-9-CM diagnosis code: V7612 which are assigned for screening mammography. Women must have had at least one mammography screening during the past 24 months to be grouped into those who had BC screening; otherwise, they were considered as not having BC screening.
Statistical analysis
Descriptive statistics were obtained using frequencies and percentages for all included factors. Chi-square tests were used to test for significant differences among the four groups based on BC stage at diagnosis (0, I, II, and III/IV). The level of statistical significance was defined at a p value B 0.05. To examine the associations between stage of BC at diagnosis and the severity of diabetes-related complications using DCSI, we used three multinomial logistic regression models. The first model assessed the unadjusted association between stage of BC at diagnosis and the severity of diabetes-related complications. The second model was used to partially adjust for biological and non-biological factors (except mammography screening use) while the third model assessed the full adjusted association after controlling for all covariates: biological factors, non-biological factors and screening mammography use. In all models, ''stage 0,'' was the reference group. The results are presented as odds ratios with their corresponding 95% confidence intervals (95% CI). All analyses were conducted using SAS 9.4 (SAS Ò version 9.4, SAS Institute Inc., Cary, NC, USA). Statistical significance was defined as a p-value B 0.05. Table 1 describes the study cohort of 7729 elderly women with pre-existing diabetes, aged 67 years and older, diagnosed with a first primary incident BC in 2004-2011. About 57% of the study cohort had at least one screening mammography during the last 24 months. A majority of the women were white (75.1%), resided in metro areas (79.3%), had at least one PCP visit during the 12 months prior to the BC diagnosis (94.5%), had no endocrinologist visits in the year that preceded BC diagnosis (88.1%), and had positive progesterone & estrogen HR (62.6% & 74%). For the most common comorbid chronic conditions, 70.4% had hyperlipidemia, 89.7% had hypertension, 28.3% had arthritis, and 15.8% had depression.
Results
With respect to DCSI, 38.4% had no diabetes-related complications, 13.1% had a DCSI = 1, 23% had a DCSI = 2, and 25.4% had a DCSI C 3. The most frequent diabetes-related complications were cardiovascular complications (45.2%), nephropathy (19.5%), and neuropathy (13.6%) (non-tabulated). Compared with women who had no diabetes complications, those with a DCSI C 3 were older, more likely to have had an endocrinologist visit, less likely to have had screening mammography, and more likely to have other comorbid conditions (arthritis, thyroid syndrome, COPD, dementia, hypertension, and depression). Table 2 shows the group differences in all the independent variables by stage of BC at diagnosis. About 15% of the cohort were diagnosed at stage 0, 38.4% stage I, 29.1% stage II, and 17.7% were diagnosed at advanced stages (stage III or stage IV). The biological factors that have significant bivariate associations with stage of BC at diagnosis were DCSI, age, race, progesterone HS, estrogen HS, thyroid disease, arthritis, COPD, dementia, hyperlipidemia, osteoporosis, and depression. The non-biological factors that were statistically significant in the Chi-square analyses were mammography screening, PCP visits, endocrinologist visits, availability of BC screening centers, census tract education, and census tract annual household income.
Elderly women who were diagnosed with advanced stages (stage III/IV) BC were more likely to have had a DCSI C 3 (29.9%) and less likely to have had screening mammography as compared to those women who were diagnosed with stage 0 (21.7%).
Regarding other factors, elderly women who were diagnosed with advanced stages (stage III/IV) BC were less likely to have positive progesterone HR, more likely to have COPD, arthritis, and dementia as compared to women who were diagnosed with stage 0 of BC. Table 1 The baseline characteristics of the study cohort
Characteristic
All women The results from the multinomial logistic regressions are reported in Table 3 . Model 1 presents the unadjusted association between the severity of diabetes complications using DCSI and stage of BC at diagnosis. In this model, the severity of diabetes complications was significantly associated with BC stage at diagnosis. Women with a DCSI = 2 were 30%, 45%, and 57% more likely to be diagnosed at stages I (OR 1.30, 95% CI 1.08-1.56), stage II (OR 1.45, 95% CI 1.20-1.76), and advanced stage (III/IV) (OR 1.57, 95% CI 1.27-1.93), respectively, as compared to those with no diabetes complications. Women with a DCSI C 3 were 20%, 50%, and 77% more likely to be diagnosed at stage I (OR 1.20, 95% CI 1.00-1.43), stage II (OR 1.50, 95% CI 1.25-1.81), and advanced stage (III/IV) (OR 1.77, 95% CI 1.45-2.17), respectively, as compared to those women with no diabetes complications. In the partial adjusted association between severity of diabetes complications and stage of BC at diagnosis, controlling for biological and non-biological factors in model 2, we found that the severity of diabetes complication (a DCSI = 2 and a DCSI C 3) continue to be significantly associated with stage of BC at diagnosis. Model 3 shows the fully adjusted association between BC stage at diagnosis and severity of diabetes complications after controlling for biological factors, non-biological factors, and use of screening mammogram. Women with a DCSI = 2 were 26% more likely to be diagnosed at stage I (OR 1.26, 95% CI 1.03-1.53) while having a DCSI C 3 was no longer an independent predictor of BC stage at diagnosis. Women who had at least one screening mammography during the two year that preceded BC diagnosis were 44%, 81%, and 91% less likely to be diagnosed with stage I (OR 0.56, 95% CI 0.47-0.67), stage II (OR 0.19, 95% CI 0.16-0.23), and advanced stages (III/IV) (OR 0.09, 95% CI 0.08-0.11), respectively, as compared to women who did not received any screening mammography.
Discussion
In this study, we examined the relationship between severity of diabetes-related complications and stage of BC at diagnosis in a large sample of elderly women with preexisting diabetes and an incident BC. Overall, severity of diabetes-related complications was associated with stage of BC at diagnosis. Adjustment for other biological and nonbiological factors did not attenuate the association between severity of diabetes complications and BC stage at diagnosis. Our findings showed that among elderly women with pre-existing diabetes, the likelihood of being diagnosed with advanced stages of BC increased from 46% in women with a moderate severity of diabetes-related complications (a DCSI = 2) to 62% in women with highest severity of diabetes-relates complications (a DCSI C 3), as compared to women with no diabetes complications.
After adjustment for BC screening in Model 3, a moderate severity of diabetes complications (a DCSI = 2) continued to be associated with 20% increase in the likelihood of being diagnosed at stage I versus stage 0 as compared to women without diabetes complications. For the association between the likelihood of being diagnosed at advanced stages (III/IV) of BC and the severity of diabetes complications, estimates were attenuated and confidence limits did not reach statistical significance. However, [18] . Although previous research found that diabetes was an independent predictor of the risk of advanced stage (III/IV) BC at diagnosis as compared to women without diabetes after accounting for BC screening mammography [2, 3] , we found that the severity of diabetes-related complications is associated with this risk indirectly through its negative impact on BC screening.
However, our study has several potential limitations that should be mentioned. Although we controlled for many biological and non-biological variables that could be associated with BC stage at diagnosis, we lacked data on other factors, such as obesity and family history of BC which could have residual confounding effect. Second, exclusions, such as 6% of BC cases with missing stage of BC may have affected the generalizability of our findings. Third, since we used claims database instead of medical records to measure DSCI, the index was measured without laboratory results. However, a study by Chang et al. found that the DCSI without laboratory results performs similar to the DCSI with laboratory information [19] .
Despite the limitations, our study included modeling a comprehensive list of biological factors (e.g., comorbid conditions and hormone receptor status) and non-biological factors (e.g., access to health care and community-related factors). To assess the severity of diabetes-related complications, we used DCSI which captures both count and severity of complications while a simple count of complications does not take the severity of each complication into account [15] . In addition to its use as a measure of diabetes severity, a study by Young et al. found that this index may be considered as a proxy measure for diabetes duration since severity index of diabetes complications was highly correlated with diabetes duration [15] . Because diabetes may remain undiagnosed for years, using DCSI as a severity measure of long-term complications probably demonstrate the consequences of biologic markers of diabetes duration [20] .
In conclusion, our study provides evidence that the severity of diabetes-related complications is associated with stage of BC at diagnosis and has an indirect association with the risk of advanced stages diagnosis of BC among women with pre-existing diabetes. The increased likelihood of advanced-stage BC diagnosis that is associated with the severity of diabetes-related complications may be mainly driven by lower rates of BC screening among those with diabetes complications.
